Mutant Metastatic Colorectal Cancer (mCRC) Market – Trends Forecast Till 2031

Market Snapshot

Market Overview

The global Mutant Metastatic Colorectal Cancer (mCRC) Market size was estimated at USD 13,500 million in 2024 and is projected to reach USD 17783.3 million in 2031 at a CAGR of 4.7 % during the forecast period 2025-2031.

Mutant metastatic colorectal cancer (mCRC) refers to a subset of colorectal cancer where the cancer has spread beyond the original site and exhibits mutations in specific genes such as KRAS, NRAS, or BRAF. These mutations impact the tumor's response to treatment and are crucial for determining the most effective therapies. As a major cause of cancer-related deaths globally, mCRC presents significant challenges in terms of treatment and management. The market for therapies targeting mCRC has expanded as innovative treatments and personalized approaches have become central to improving patient outcomes.

The scope of the mCRC market encompasses a variety of treatment modalities, including chemotherapy, targeted therapy, immunotherapy, and newer forms of personalized medicine. The growing understanding of genetic mutations in mCRC has led to the development of targeted therapies that aim to inhibit the specific molecular pathways responsible for cancer progression. In addition to pharmaceutical interventions, companion diagnostics and genetic testing are critical components, allowing for the identification of patients who may benefit from targeted treatments. The market also includes both branded and generic drugs, along with investigational therapies in clinical trials.

Trends in the mCRC market reflect a shift toward precision medicine and more effective treatments that address the genetic profile of individual patients. The rise in the use of immunotherapies, such as immune checkpoint inhibitors, is driving substantial growth in the market, as these therapies have shown promise in patients with specific mutations. Additionally, combination therapies that pair traditional treatments with newer drug classes are gaining traction, offering potential for improved outcomes. Advances in molecular diagnostics are enabling clinicians to make more informed decisions, further enhancing the precision of treatments and potentially extending survival rates for patients.

Several drivers are fueling the expansion of the mCRC market, including an increasing global incidence of colorectal cancer, improved survival rates due to new therapies, and the growing demand for personalized medicine. The aging population is another key factor, as the risk of mCRC increases with age. Moreover, ongoing research and development in the field of oncology, alongside regulatory approvals for novel treatments, are contributing to the market's growth. With major pharmaceutical companies and biotech firms investing heavily in the development of mCRC-specific drugs, the market is expected to continue evolving rapidly, offering new hope for patients with this complex and challenging disease.

Delvens Industry Expert's Standpoint

Experts in the Mutant Metastatic Colorectal Cancer (mCRC) Market highlight several key trends driving growth and innovation. The mutant metastatic colorectal cancer (mCRC) market is driven by the growing prevalence of the disease, advancements in personalized medicine, and the emergence of targeted therapies. This market includes a range of treatment options such as chemotherapy, immunotherapy, and genetic-based therapies tailored to specific mutations like KRAS, NRAS, and BRAF. Key trends include the increasing use of combination therapies and immunotherapies, along with improved molecular diagnostics that enable more precise treatment choices. Factors like an aging population, enhanced survival rates due to innovative therapies, and ongoing research and development are driving market growth, with substantial investments from pharmaceutical and biotech companies focused on mCRC-specific treatments.

Market Portfolio

Key Findings

• The market is categorized by drug class into chemotherapy, immunotherapy, and others. The immunotherapy segment led the market with a revenue share of 78.5% in 2024 and is anticipated to experience the highest compound annual growth rate (CAGR) of 6.1% during the forecast period. Immunotherapies have demonstrated fewer adverse effects than chemotherapy, which is often hindered by non-specificity, toxic side effects, and the development of resistance. These limitations are expected to drive greater adoption of immunotherapeutic treatments in the future.

• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America region is projected to hold the largest market share. Factors such as increasing global incidence of colorectal cancer, rising adoption of personalized medicine, advancements in molecular diagnostics, growth in immunotherapy use, an aging population, improved survival rates, high demand for targeted therapies, ongoing research and development, regulatory approvals for novel treatments, and growing investments from pharmaceutical and biotech companies have triggered the Mutant Metastatic Colorectal Cancer (mCRC) Market in the region.

Regional Analysis

North America to Dominate the Market

• In 2024, North America captured a revenue share of 39.2% in the colorectal cancer (CRC) therapeutics market. The market is expected to experience steady growth, driven by the high incidence of CRC, increased treatment rates, and higher medication prices compared to other regions. Additionally, changing lifestyle factors, such as the growing consumption of alcohol, are contributing to the market's expansion. The International Agency for Research on Cancer (IARC) has linked alcohol consumption to CRC, with approximately 55% of the adult population in the U.S. reporting alcohol use in 2021.

• The Asia Pacific region is forecasted to experience the highest compound annual growth rate (CAGR) of 7.3% during the forecast period, fuelled by the rising geriatric population and the increasing involvement of public and private sectors in promoting colorectal cancer awareness. A study published in the National Library of Medicine in April 2022 revealed that pilot population-based CRC screening programs have been introduced in some administrative regions of China, which are expected to enhance early diagnosis and treatment of the disease.

Competitive Landscape

• Amgen, Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• Lilly
• Merck & co., Inc.
• F. Hoffmann-La Roche Ltd.
• Sanofi

Recent Developments

• In December 2024, EndoQuest Robotics received FDA IDE approval for a clinical trial to assess the use of its surgical robot in colorectal lesion removal. The trial will include 50 participants across five sites in the U.S.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
• Gain authentic and granular data access for the Mutant Metastatic Colorectal Cancer (mCRC) Market to understand the trends and the factors involved in changing market situations.
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope